The Technical Analyst
Ovid Therapeutics Inc [OVID]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Ovid Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $2.20
Last updated: 8 aug 2022 - 0:07
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 154.92 mill |
| EPS: | -0.946 |
| P/E: | 0.000 |
| Earnings Date: | Aug 15, 2022 |
| SharesOutstanding: | 70.42 mill |
| Avg Daily Volume: | 0.182 mill |
| RATING 2022-08-05 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$5.41 (146.04%) $3.21 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.10 - 2.30 ( +/- 4.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
| 2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
| 2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 5 750 000 | Common Stock |
| 2022-07-01 | Takeda Pharmaceutical Co Ltd | Buy | 1 250 | Series A Convertible Preferred Stock |
| 2022-04-08 | Bernstein Karen | Buy | 69 424 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 94.53 |
| Last 100 transactions |
| Buy: 15 161 448 | Sell: 34 017 |
Forecast:
16:00 - $2.20
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.20
Forecast 2: 16:00 - $2.20
Forecast 3: 16:00 - $2.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.20 (0.00% ) |
| Volume | 0.0357 mill |
| Avg. Vol. | 0.182 mill |
| % of Avg. Vol | 19.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
OVID
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Latest Press Releases
2022-05-10 08:00:00 - Press Release
Ovid Therapeutics Reports First Quarter 2022 Financial Results And Corporate Highlights
New york, may 10, 2022 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the first quarter ended march 31, 2022.
2022-03-15 08:00:00 - Press Release
Ovid Therapeutics Reports Business Update, Fourth Quarter And Full Year 2021 Financial Results
New york, march 15, 2022 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended december 31, 2021.
2022-03-04 08:00:00 - Press Release
Ovid Therapeutics To Participate At The Cowen 42nd Annual Health Care Conference
New york, march 04, 2022 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “orphan neuro and neuromuscular” panel discussion at the cowen 42nd annual health care conference on monday, march 7, 2022, at 9:10 a.m. et.
2022-02-08 08:00:00 - Press Release
Healx And Ovid Therapeutics To Enter Strategic Partnership
– ovid to license gaboxadol to healx –
2022-01-03 06:30:00 - Press Release
Ovid Therapeutics Expands Epilepsy Franchise With Novel Kcc2 Activators
New york, jan. 03, 2022 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the company has entered into an exclusive license agreement with astrazeneca for a library of early-stage small molecules targeting the kcc2 transporter, including lead candidate, ov350. the company seeks to optimize and accelerate development of these kcc2 transporter activators in epilepsies and potentially other neuropathic conditions.
Latest News
2022-04-26 07:17:21 - InvestorPlace
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace.
2022-04-08 08:00:00 - GlobeNewsWire
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.
2021-10-07 08:30:00 - GlobeNewsWire
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.
2021-07-08 16:30:00 - GlobeNewsWire
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
2021-06-18 17:09:55 - Seeking Alpha
Ovid Therapeutics: Good Entry Point For Investors
There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential.
2021-05-20 12:02:32 - Zacks Investment Research
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
2021-05-12 08:00:00 - GlobeNewsWire
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.
2021-04-30 11:37:02 - InvestorPlace
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover appeared first on InvestorPlace.
2021-03-30 09:20:26 - Pulse2
OVID Stock Price Increased Over 5% Pre-Market: Why It Happened
The stock price of Ovid Therapeutics Inc. (NASDAQ: OVID) increased by over 5% pre-market. This is why it happened.
2021-03-10 11:54:25 - InvestorPlace
8 Biotech Penny Stocks for Investors to Watch
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.